← All peptidesPDA-V1 attestation Citations
verifiedBioGate · GREENGrade B
Cagrilintide
KCNTATCATNRLANFLVRSSNNLGPVLPPTNVGSNTYLong-acting amylin analog; suppresses appetite and gastric emptying. In Phase 3 as CagriSema combination with semaglutide.
disulfide C2-C7γGlu-C18 lipid sidechainamidated C-terminus
MW
3890.40
Length
37aa
Posterior
39.3%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · disulfide C2-C7
Cryptographic chain of custody.
- Outer PDA hash
- Inputs hash
- Merkle root
- TEE attestation
- Protocol version
- PDA-V1
- Source
- peptide-md
- Model version
- structure-fm-2026.04
- Candidates emitted
- 2
- Signed
- 2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with
@peptide-md/verifier.Real-world evidence
Cohort-attested outcomes.
Cohorts
1
Participants
216
Mean Δ
+2.32
Δ HRV ms (8-week) · 95% CI [0.8, 3.83]
IPNFT · Molecule IPNFT V2Solana
Cagrilintide
747c54…20717cRoyalty cascade
4.07%
Holders
115
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Source literature.
Grade A2021 · Lancet
Once-weekly cagrilintide for weight management in people with overweight and obesity
Lau DCW et al.